Results 1 to 10 of about 266,137 (295)

Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling [PDF]

Molecular Metabolism, 2021
Objectives: Receptor Activity-Modifying Protein 2 (RAMP2) is a chaperone protein which allosterically binds to and interacts with the glucagon receptor (GCGR).
Emma Rose McGlone, Yusman Manchanda, Ben Jones, Phil Pickford, Asuka Inoue, David Carling, Stephen R. Bloom, Tricia Tan, Alejandra Tomas   +8 more
doaj   +7 more sources

Loss of receptor activity-modifying protein 2 in mice causes placental dysfunction and alters PTH1R regulation. [PDF]

PLoS ONE, 2017
Receptor activity-modifying protein 2 (Ramp2) is a single-pass transmembrane protein that heterodimerizes with several family B G-protein coupled receptors to alter their function.
Mahita Kadmiel, Brooke C Matson, Scott T Espenschied, Patricia M Lenhart, Kathleen M Caron   +4 more
doaj   +5 more sources

Receptor and secreted targets of Wnt-1/β-catenin signalling in mouse mammary epithelial cells [PDF]

BMC Cancer, 2005
Background Deregulation of the Wnt/ β-catenin signal transduction pathway has been implicated in the pathogenesis of tumours in the mammary gland, colon and other tissues.
Enver Tariq, Kenny Paraic A, Ashworth Alan   +2 more
doaj   +5 more sources

Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis [PDF]

Arthritis Research & Therapy
Background Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used.
Yuji Nozaki, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Yumiko Wada, Takuya Kotani, Tohru Takeuchi, Toshihiko Hidaka, Shoichi Hino, Toshiaki Miyamoto, Hirofumi Miyake, Kazunari Hatta, Kenji Mamoto, Yutaro Yamada, Tadashi Okano, Takaichi Okano, Jun Saegusa, Masahiro Horita, Keiichiro Nishida, Koji Kinoshita, Shinya Rai   +20 more
doaj   +2 more sources

New characterization of dihydroergotamine receptor pharmacology in the context of migraine: utilization of a β-arrestin recruitment assay

Frontiers in Neurology, 2023
IntroductionDihydroergotamine mesylate (DHE) is an established effective acute therapy for migraine and is often characterized by its broad receptor pharmacology.
Lisa McConnachie, Lisa McConnachie, Peter J. Goadsby, Peter J. Goadsby, Robert E. Vann, Sutapa Ray, Stephen B. Shrewsbury, Sheena K. Aurora   +7 more
doaj   +1 more source

Effect of Xiongmatang Extract on Behavioral and TRPV1-CGRP/CGRP-R Pathway in Rats With Migraine

Frontiers in Pharmacology, 2022
Migraine is a complex neurovascular disease, which seriously affects the quality of life in patients. This study aimed to evaluate the effect of Xiongmatang (XMT) extract on rats with migraine induced by inflammatory soup and the underlying mechanisms ...
Dingding Liu, Lulu Chang, Jingru Wang, Qiang Zhu, Ning Jiang, Mudassar Azhar, Ayaz Ahmed, Guirong Zeng   +7 more
doaj   +1 more source

Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations

Scientific Reports, 2023
Splice modulating antisense oligomers (AOs) are increasingly used to modulate RNA processing. While most are investigated for their use as therapeutics, AOs can also be used for basic research.
Jessica M. Cale, Kristin A. Ham, Dunhui Li, Craig S. McIntosh, Gerald F. Watts, Steve D. Wilton, May T. Aung-Htut   +6 more
doaj   +1 more source

Determining the Effects of Differential Expression of GRKs and β-arrestins on CLR-RAMP Agonist Bias

Frontiers in Physiology, 2022
Signalling of the calcitonin-like receptor (CLR) is multifaceted, due to its interaction with receptor activity modifying proteins (RAMPs), and three endogenous peptide agonists.
Abigail Pearce, Theo Redfern-Nichols, Matthew Harris, David R. Poyner, Mark Wigglesworth, Graham Ladds   +5 more
doaj   +1 more source

Improved SARS-CoV-2 Spike Glycoproteins for Pseudotyping Lentiviral Vectors

Frontiers in Virology, 2021
The spike (S) glycoprotein of SARS-Cov-2 facilitates viral entry into target cells via the cell surface receptor angiotensin-converting enzyme 2 (ACE2).
Paul G. Ayoub, Arunima Purkayastha, Jason Quintos, Curtis Tam, Lindsay Lathrop, Kevin Tam, Marlene Ruiz, Roger P. Hollis, Brigitte N. Gomperts, Brigitte N. Gomperts, Brigitte N. Gomperts, Donald B. Kohn, Donald B. Kohn, Donald B. Kohn, Donald B. Kohn, Donald B. Kohn   +15 more
doaj   +1 more source

Pharmacological levels of withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells [PDF]

, 2014
Withaferin A (WA) isolated from Withania somnifera (Ashwagandha) has recently become an attractive phytochemical under investigation in various preclinical studies for treatment of different cancer types. In the present study, a comparative pathway-based
A Albini, A Cock-Rada, A Grigoriadis, An Wouters, AP Mazar, B Castellana, B Grin, B Jayaprakasam, D Hanahan, D Sarrio, Dariusz Ratman, DG Johnson, DR Hurst, ER Hahm, Erik Fransen, F Pereira, F Zambelli, Filip Lardon, G Chiappetta, G Natoli, GK Smyth, Guy Van Camp, H Yu, Ilse M. Beck, J Chia, J Lee, J Lee, JB Mitchem, JH Nijwening, JJ Steffan, JT Thaiparambil, K Belguise, K Miyazaki, Karen Heyninck, Karolien De Bosscher, Katarzyna Szarc vel Szic, KD Brown, Ken Declerck, Ken Op de Beeck, L Dumartin, L Ma, LC Mishra, LP Blair, M Endo, M Kaileh, M Tian, Marc Bracke, MD Edmonds, MJ Duffy, MJ Dunning, MN Ndlovu, N Brunner, N Pouliot, N Widodo, O De Wever, P Chi, PH O'Donnell, PJ Boimel, R Nanda, R Santana-Davila, Rajeev Samant, S Mirza, S Ramadoss, S Subbaram, SC Smith, SD Stan, SD Stan, SL Floor, TW Rockway, W Vanden Berghe, Wim Vanden Berghe, WL Berry, WW Bhat, Y He, YJ Surh   +74 more
core   +6 more sources